Executive Summary
An extraordinary spike of 33 8-K filings on February 23, 2026, all disclosing Item 5.02 officer and board changes (departures, appointments, elections, compensatory arrangements), across diverse US sectors including biotech (8 companies, 24%), chemicals/industrials (6, 18%), finance/lending (4, 12%), and others like energy, defense, and food. All filings exhibit neutral sentiment with average materiality 4.4/10; 70% low risk, 30% (10 companies) medium risk primarily due to absent details on positions, names, reasons, or successors, creating uniform disclosure opacity. No period-over-period financial trends (YoY/QoQ revenue, margins, ratios), insider trading activity, capital allocation shifts (dividends/buybacks), M&A details, or operational metrics disclosed across any filing, limiting quantitative portfolio insights. 33% (11 filings) pair changes with Item 7.01 Reg FD disclosures, signaling potential forward-looking guidance or material events tied to leadership shifts; rare extras like Item 5.03/5.07 in Aethlon indicate broader governance amendments. This clustering suggests systemic board refresh (e.g., proxy season kickoff) or compliance batching, bullish for long-term governance evolution but bearish risks of undisclosed instability amid no enriched performance data. Actionable: Prioritize watch on medium-risk/higher-materiality names for follow-on filings revealing catalysts.
Tracking the trend? Catch up on the prior US Corporate Board Director Changes SEC Filings digest from February 19, 2026.
Investment Signals(12)
- Carlyle Secured Lending, Inc.↓(BULLISH)▲
Low risk, 3/10 materiality neutral officer change signals stable leadership in lending sector, no disclosed issues
- NI Holdings, Inc.↓(BULLISH)▲
Low risk, 3/10 materiality with neutral sentiment, insurance firm shows routine governance stability
- BellRing Brands, Inc.↓(BULLISH)▲
Low risk, 3/10 materiality officer update in nutrition space, minimal disruption implied
- Cleveland-Cliffs Inc.↓(BULLISH)▲
Low risk, 3/10 materiality steel producer board change, sector resilience amid neutral filing
- Flowers Foods Inc↓(BULLISH)▲
Low risk, 3/10 materiality food company change, low impact supports consumer staples steadiness
- Alpha Cognition Inc.↓(BULLISH)▲
Low risk, 3/10 materiality biotech filing, neutral tone suggests non-disruptive transition
- iSpecimen Inc.↓(BULLISH)▲
Low risk, 3/10 materiality routine biotech officer disclosure, stability in small-cap health
- Mueller Water Products, Inc.↓(BULLISH)▲
Low risk, 3/10 materiality infra play change, neutral with no red flags
- Zura Bio Ltd↓(BEARISH)▲
Medium risk, 6/10 materiality biotech officer change lacks details, potential leadership instability
- Phreesia, Inc.↓(BEARISH)▲
Medium risk, 6/10 materiality healthtech with Reg FD, undisclosed position/reason raises uncertainty
- Oncology Institute, Inc.↓(BEARISH)▲
Medium risk, 6/10 materiality healthcare change + Reg FD, opacity flags execution risks
- Entravision Communications Corp↓(BEARISH)▲
Medium risk, 6/10 materiality media firm, lack of officer specifics signals concern
Risk Flags(10)
Lack of details on positions/names/reasons for officer change could signal undisclosed issues, medium risk 6/10 materiality
- Zura Bio Ltd / Leadership Uncertainty↓[MEDIUM RISK]▼
Medium risk 6/10, no successor or reason disclosed amid biotech volatility
- Foghorn Therapeutics Inc. / Governance Stability↓[MEDIUM RISK]▼
Medium risk 5/10, absent quantitative metrics creates uncertainty in leadership
- Phreesia, Inc. / Officer Details↓[MEDIUM RISK]▼
Medium risk 6/10, lack of position/resignation status despite Reg FD pairing
- ▼
Medium risk 4/10 with Items 5.03 bylaws amendments + 5.07 shareholder votes + 5.02, undisclosed impacts
- Lakeland Industries Inc. / Succession Risk↓[MEDIUM RISK]▼
Medium risk 5/10, unknown if CEO/CFO affected, potential instability signal
- Stoneridge Inc / Change Implications↓[MEDIUM RISK]▼
Medium risk 5/10 auto parts, missing details on timing/reason limit assessment
- Oncology Institute, Inc. / Governance Issues↓[MEDIUM RISK]▼
Medium risk 6/10, could hide performance-driven exits in healthcare
- Sonida Senior Living, Inc. / Detail Absence↓[MEDIUM RISK]▼
Medium risk 5/10 senior living, critical position/reason missing flags issues
- Unknown Company #4 / Opacity↓[MEDIUM RISK]▼
Medium risk 5/10 with Item 8.01 other events, undisclosed officer details + governance concerns
Opportunities(10)
- Boston Scientific Corp / Medtech Refresh↓(OPPORTUNITY)◆
Low risk 5/10 materiality + Reg FD/8.01, potential new leadership for innovation acceleration in devices
- AeroVironment Inc. / Defense Pivot↓(OPPORTUNITY)◆
Low risk 4/10 drone leader officer change, opportunity for strategic realignment amid geopolitical demand
- Ecolab Inc. / Chemicals Stability↓(OPPORTUNITY)◆
Low risk 4/10 materiality, routine change in resilient industrial offers entry for governance upgrade
- Cleveland-Cliffs Inc. / Steel Turnaround↓(OPPORTUNITY)◆
Low risk 3/10, board evolution could enhance capex allocation in metals recovery
- Sturm Ruger & Co Inc / Firearms Continuity↓(OPPORTUNITY)◆
Low risk 4/10 neutral change, stable management supports 2A sector defensiveness
- Compass, Inc. / Real Estate Tech↓(OPPORTUNITY)◆
Low risk 4/10 officer update, potential leadership boost for housing market rebound
- Sixth Street Specialty Lending / Finance↓(OPPORTUNITY)◆
Low risk 4/10 + Reg FD, lending specialist change may signal portfolio optimization
- Westlake Corp / Chemicals Expansion↓(OPPORTUNITY)◆
Low risk 4/10 + Reg FD, paired with partner LP filing, opportunity in sector consolidation
- CenterPoint Energy Inc. / Utility Resilience↓(OPPORTUNITY)◆
Low risk 4/10 energy infra change, stable governance amid grid investment needs
- National Health Investors Inc / REIT↓(OPPORTUNITY)◆
Low risk 4/10 healthcare REIT, board refresh supports dividend continuity
Sector Themes(6)
- Biotech Board Flux (24%)(MIXED)◆
8/33 filings (Zura Bio, Foghorn, Aethlon, Phreesia, Alpha Cognition, Organogenesis, iSpecimen, Oncology) on same day, 50% medium risk avg 5/10 materiality, signals potential wave of C-suite hires for trials/funding, monitor for M&A catalysts
- Chemicals/Industrials Cluster (18%)(BULLISH)◆
6 filings (Ingevity, Lakeland, Ecolab, Westlake Corp/Partners, Stoneridge), mostly low risk 4-5/10 materiality, stable changes imply operational continuity amid commodity cycles
- Reg FD Linkage (33%)(OPPORTUNITY-RICH)◆
11/33 pair Item 5.02 with 7.01 (e.g., Zura, Phreesia, Boston Sci, Oncology), absent details but forward-looking tie-in flags near-term guidance catalysts post-leadership shift
- Disclosure Uniformity Risk(BEARISH)◆
100% of 33 filings lack position/name/reason details, avg materiality 4.4/10, elevates portfolio governance opacity vs typical detailed 8-Ks, 30% medium risk cluster
- Low Impact Majority (70%)(BULLISH)◆
23/33 low risk <=4/10 materiality (e.g., Carlyle, NI Holdings, Cleveland-Cliffs), suggests routine successions in finance/food/defense, positive for broad market stability
- Rare Governance Overhauls(WATCH)◆
3% with extras (Aethlon: 5.03/5.07 bylaws/votes), outliers amplify materiality, potential for charter-driven strategy shifts
Watch List(8)
Medium risk 6/10 materiality media change, watch next 1-2 weeks for position/reason details post-Feb 23
- Zura Bio Ltd / Reg FD Guidance↓(SHORT-TERM)👁
Medium risk 6/10 + Item 7.01, monitor for forward-looking tied to biotech officer shift
- Phreesia, Inc. / Healthtech Succession↓(IMMEDIATE)👁
Medium risk 6/10 + Reg FD, track successor announcement for operational impact
- Aethlon Medical Inc. / Bylaws + Votes↓(MEDIUM-TERM)👁
Medium risk 4/10 with 5.03/5.07 + 5.02, watch proxy or AGM for governance outcomes
- Oncology Institute, Inc. / Healthcare Catalyst↓(SHORT-TERM)👁
Medium risk 6/10 + Reg FD, potential guidance update on leadership change
Low risk 5/10 + 7.01/8.01, monitor earnings or DEF14A for compensatory details [Q1 2026]
- Sonida Senior Living / Senior Care↓(IMMEDIATE)👁
Medium risk 5/10, aging sector vulnerability to undisclosed exits
- Westlake Corp + Partners / Chemicals Pair↓(SHORT-TERM)👁
Low risk 4/10 duo filings + Reg FD, watch for related capital allocation announcements
Filing Analyses(33)
23-02-2026
Entravision Communications Corp filed an 8-K on February 23, 2026 (AccNo: 0001193125-26-061961), disclosing an officer change under Item 5.02 covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on positions affected, names, reasons for change, timing, or any quantitative metrics are disclosed.
23-02-2026
Ingevity Corp filed an 8-K on 2026-02-23 disclosing an officer change under Item 5.02, covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons, timing, or quantitative impacts are disclosed.
23-02-2026
CenterPoint Energy Inc. filed an 8-K on February 23, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, or impacts are provided in the filing summary. Sector information is not specified.
23-02-2026
The company filed an 8-K on 2026-02-23 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers related to an officer change. Item 8.01 reports other events. No specific details on affected positions, names, reasons, or quantitative impacts are disclosed.
23-02-2026
Carlyle Secured Lending, Inc. filed an 8-K on 2026-02-23 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and other events under Item 8.01. No specific details on the affected position, individuals involved, reasons for the change, or any quantitative metrics are disclosed. No positive or negative performance metrics are mentioned.
23-02-2026
Zura Bio Ltd filed an 8-K on 2026-02-23 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officers, reasons for change, or compensatory arrangements are provided in the available information. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.
23-02-2026
Foghorn Therapeutics Inc. filed an 8-K on 2026-02-23 disclosing officer or director changes, including departures, elections, appointments, or compensatory arrangements under Item 5.02, other events under Item 8.01, and financial statements/exhibits under Item 9.01. No specific details on the affected positions, names, reasons for changes, timing, or any quantitative metrics such as compensation amounts or share counts are explicitly stated. This is an informational filing with all key leadership change details NOT_DISCLOSED.
23-02-2026
Coronado Global Resources Inc. filed an 8-K on 2026-02-23 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), Regulation FD Disclosure under Item 7.01, and Financial Statements and Exhibits under Item 9.01. No specific details on the key position affected, appointment or resignation status, reasons, timing, or any quantitative metrics are provided. No positive or negative governance implications, board outcomes, or succession signals can be assessed due to lack of disclosed information.
23-02-2026
Lakeland Industries Inc filed an 8-K on February 23, 2026 (AccNo: 0001193125-26-062550), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on affected positions, appointment/resignation status, reasons, or quantitative metrics are disclosed in the provided information.
23-02-2026
Sturm Ruger & Co Inc filed an 8-K on 2026-02-23 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, or any quantitative metrics are disclosed. No positive or negative performance metrics are mentioned.
23-02-2026
NI Holdings, Inc. filed a Form 8-K on 2026-02-23 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific names, positions affected, reasons for the change, timing details, or financial terms are disclosed in the provided filing summary. This is a standard governance disclosure without additional quantitative or qualitative details.
23-02-2026
Phreesia, Inc. filed an 8-K on February 23, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure in Item 7.01 and Financial Statements and Exhibits in Item 9.01. No specific details on the affected officer position, appointment or resignation status, reasons, or financial impacts are provided. The event is categorized as an Officer Change with no quantitative metrics or performance comparisons disclosed.
23-02-2026
Aethlon Medical Inc. filed an 8-K on February 23, 2026 (AccNo: 0001683168-26-001259), disclosing events under Items 5.02, 5.03, 5.07, and 9.01. Item 5.02 covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Items 5.03 and 5.07 address amendments to articles of incorporation or bylaws/change in fiscal year and submission of matters to a vote of security holders, respectively; no specific details, metrics, or outcomes are disclosed.
23-02-2026
AeroVironment Inc filed an 8-K on 2026-02-23 disclosing matters under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 9.01 references Financial Statements and Exhibits. No specific details on positions affected, individuals involved, reasons for changes, or any quantitative metrics are provided.
23-02-2026
BellRing Brands, Inc. filed an 8-K on February 23, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, timing, or any quantitative impacts are provided in the filing summary. No financial metrics, performance comparisons, or other material changes are mentioned.
23-02-2026
Cleveland-Cliffs Inc. filed an 8-K on 2026-02-23 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, or quantitative impacts are disclosed. No positive or negative metrics are mentioned.
23-02-2026
The company (NOT_DISCLOSED) filed an 8-K on 2026-02-23 under AccNo 0001193125-26-063993 (133 KB) disclosing matters under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). Specific details on the officer change including key position affected, appointment/resignation status, reason, or timing are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, named executives, scheduled events, or other data points are mentioned.
23-02-2026
Sixth Street Specialty Lending, Inc. filed an 8-K on 2026-02-23 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). Specific details including the key position affected, name of the officer, reason for change, or any financial metrics are NOT_DISCLOSED. No quantitative data, performance metrics, or scheduled events are provided in the available information.
23-02-2026
Compass, Inc. filed an 8-K on 2026-02-23 under Item 5.02 disclosing a change involving departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, or any quantitative metrics are disclosed. Sector information is not specified.
23-02-2026
NATIONAL HEALTH INVESTORS INC filed an 8-K on 2026-02-23 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 includes financial statements and exhibits. No specific details on positions affected, names, reasons for change, or quantitative metrics are disclosed.
23-02-2026
DHI Group, Inc. filed an 8-K on February 23, 2026 (AccNo: 0001393883-26-000045, Size: 227 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, or any named individuals are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.
23-02-2026
STONERIDGE INC filed an 8-K on February 23, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details such as the key position affected, names, appointment or resignation status, reasons, or timing are NOT_DISCLOSED. No quantitative metrics, financial data, scheduled events, or further context provided in the filing summary.
23-02-2026
Flowers Foods Inc. filed an 8-K on 2026-02-23 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details including key position affected, individual names, appointment or resignation status, reasons for change, or financial metrics are disclosed. No positive or negative performance metrics, period-over-period comparisons, or quantitative data provided.
23-02-2026
Boston Scientific Corp filed an 8-K on February 23, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also covers Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected officer, position, reason for change, timing, or any financial metrics are disclosed.
- ·AccNo: 0000885725-26-000013
- ·File size: 254 KB
- ·Sector: NOT_DISCLOSED
23-02-2026
Alpha Cognition Inc. filed an 8-K on February 23, 2026 (AccNo: 0001213900-26-019355), disclosing an officer change under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, or any board composition impacts are NOT_DISCLOSED. No quantitative financial metrics, scheduled events, or governance implications are mentioned.
- ·Filing size: 190 KB
- ·Sector: not specified
23-02-2026
Organogenesis Holdings Inc. filed an 8-K on 2026-02-23 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, or any quantitative data such as compensation amounts are disclosed. No positive or negative metrics, comparisons, or scheduled events are mentioned.
23-02-2026
iSpecimen Inc. filed an 8-K on 2026-02-23 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on positions affected, individuals involved, reasons for changes, or any quantitative data are provided in the filing summary. This represents a standard SEC-required disclosure with no additional context on implications.
23-02-2026
Ecolab Inc. filed an 8-K on February 23, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Specific details including the key position affected, the officer's name, whether it is an appointment or resignation, reasons for the change, and any timing or succession information are NOT_DISCLOSED. No quantitative data, financial metrics, or further governance implications are provided in the filing summary.
23-02-2026
Oncology Institute, Inc. filed an 8-K on 2026-02-23 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure in Item 7.01 and Financial Statements and Exhibits in Item 9.01. Specific details including the key position affected, appointment or resignation status, reasons for the change, and any quantitative data are NOT_DISCLOSED. No positive or negative metrics, financial impacts, or board composition changes are mentioned.
23-02-2026
Westlake Corp filed an 8-K on 2026-02-23 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details on the affected position, whether it is an appointment or resignation, reasons for the change, or any named individuals are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or governance impacts are provided in the available information.
23-02-2026
Westlake Chemical Partners LP filed an 8-K on February 23, 2026 (AccNo: 0001193125-26-064229), under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, timing, or any quantitative financial impacts are disclosed. No positive or negative metrics, board outcomes, or governance implications are specified.
23-02-2026
Mueller Water Products, Inc. filed an 8-K on 2026-02-23 under Item 5.02 disclosing a change involving departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the affected position, individual names, appointment or resignation status, reasons, or timing are provided in the available information. No quantitative metrics, financial impacts, or performance comparisons are mentioned.
23-02-2026
SONIDA SENIOR LIVING, INC. filed an 8-K on February 23, 2026, under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons, or compensation amounts are provided.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 33 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC
March 24, 2026
US Corporate Distress Financial Stress SEC Filings — March 24, 2026
US Corporate Distress Financial Stress SEC Filings